Impact ledger
Ionis Pharmaceuticals, Inc. (IONS): the developments shaping its investment case
Follow the evidence affecting Ionis Pharmaceuticals, Inc.'s demand outlook, valuation assumptions. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Ionis Pharmaceuticals, Inc. · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-24 · 3 reports
Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease
Channel: Direct clinical trial success leading to potential regulatory submission and future commercialization. Increased probability of milestone payments and royalty streams.
Bullish· 1-3m
2026-09-24
Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy Therapies
Channel: Direct clinical trial success leading to potential regulatory approval and future revenue streams.
Bullish· 1-3m
2026-09-23
Roche to Acquire Ionis Pharmaceuticals, Inc.
Channel: Acquisition premium and certainty of deal closing. Positive clinical trial results for a key pipeline asset.
Bullish· 1-5d
Evidence affecting valuation assumptions
Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.
| Date | Assumption | Direction | Interpretation |
|---|---|---|---|
| 2026-09-23 | revenue | Bullish | Positive Phase 3 interim data triggers eligibility for regulatory and sales milestone payments and future royalties from partner Roche. |
| 2026-09-07 | revenue | Bearish | Phase 3 Lp(a)HORIZON study for pelacarsen did not meet primary endpoint, likely impacting future royalty and milestone revenue expectations from partner Novartis. |
| 2026-09-07 | multiple | Bullish | Target re-rates to bid premium until close. |
| 2026-09-07 | revenue | Bearish | Phase 3 Lp(a)HORIZON study for pelacarsen did not meet its primary endpoint, likely impacting future royalty and milestone revenue expectations from partner Novartis. |
Event impact log
14 events mapped to IONS since 2026-08-26. Evidence through 2026-09-25.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-25 | ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share | Increased competition in the oligonucleotide therapeutic space, potential for new comparative data. | mixed | 3-12m | 0.20 |
| 2026-09-24 | Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease | Direct clinical trial success leading to potential regulatory submission and future commercialization. Increased probability of milestone payments and royalty streams. | Bullish | 1-3m | 0.90 |
| 2026-09-24 | Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney disease | Direct clinical trial success for key pipeline assets, triggering potential milestone payments and future royalties. | Bullish | 1-3m | 0.90 |
| 2026-09-24 | Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy Therapies | Direct clinical trial success leading to potential regulatory approval and future revenue streams. | Bullish | 1-3m | 0.90 |
| 2026-09-24 | Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN Programs | Direct positive clinical trial results for key pipeline assets, leading to potential regulatory approval and commercialization. | Bullish | 1-3m | 0.90 |
| 2026-09-23 | Roche to Acquire Ionis Pharmaceuticals, Inc. | Acquisition premium and certainty of deal closing. Positive clinical trial results for a key pipeline asset. | Bullish | 1-5d | 0.90 |
| 2026-09-21 | Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and Eplontersen | Direct impact from clinical trial failures, reducing future revenue potential and increasing R&D risk perception. | Bearish | 1-3m | 0.90 |
| 2026-09-21 | Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targets | Direct impact of clinical trial setbacks on pipeline value and investor sentiment, despite analyst targets. | Bearish | 1-3m | 0.90 |
| 2026-09-21 | Ionis slides over 40% year-to-date following late-stage clinical setbacks | Direct impact of clinical trial failures on pipeline value and future revenue prospects. Investor sentiment shift. | Bearish | 1-3m | 0.90 |
| 2026-09-21 | Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacks | Direct impact on future revenue potential and increased R&D costs due to trial delays/failures. Investor sentiment deterioration. | Bearish | 3-12m | 0.90 |
| 2026-09-21 | Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacks | Direct loss of future revenue potential from failed drug candidates; increased R&D risk perception; potential impairment of intangible assets. | Bearish | 1-3m | 0.90 |
| 2026-09-12 | FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy | Increased competition in the Spinal Muscular Atrophy (SMA) treatment market. | Bearish | 1-3m | 0.60 |
| 2026-09-05 | Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint | Indirect impact on investor sentiment and perceived risk for other lipoprotein(a)-lowering therapies, as Ionis developed pelacarsen. | Bearish | 1-3m | 0.60 |
| 2026-08-26 | Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms | Increased investor attention on neurodegenerative drug development, potential for partnership or competitive landscape shifts. | watch | 1-3m | 0.60 |
Continue this research
Build your Ionis Pharmaceuticals, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the IONS entity page →